WALDEMAR PRIEBE

TitleProfessor
InstitutionMD Anderson
DepartmentExperimental Therapeutics
Address1901 East Road
Houston TX 77054-3005
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kalinowska M, Golebiewska E, Swiderski G, Meczynska-Wielgosz S, Lewandowska H, Pietryczuk A, Cudowski A, Astel A, Swislocka R, Samsonowicz M, Zlowodzka AB, Priebe W, Lewandowski W. Plant-Derived and Dietary Hydroxybenzoic Acids-A Comprehensive Study of Structural, Anti-/Pro-Oxidant, Lipophilic, Antimicrobial, and Cytotoxic Activity in MDA-MB-231 and MCF-7 Cell Lines. Nutrients. 2021 Sep 04; 13(9). PMID: 34578985.
      Citations:    Fields:    Translation:HumansCells
    2. McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, McGrath M, Sajadi MM, Harris AD, Clement J, Dybas JM, Aykin-Burns N, Guarnieri JW, Singh LN, Grabham P, Baylin SB, Yousey A, Pearson AN, Corry PM, Saravia-Butler A, Aunins TR, Nagpal P, Meydan C, Foox J, Mozsary C, Cerqueira B, Zaksas V, Singh U, Wurtele ES, Costes SV, Galeano D, Paccanaro A, Meinig SL, Hagan RS, Bowman NM, Wolfgang MC, Altinok S, Sapoval N, Treangen TJ, Frieman M, Vanderburg C, Wallace DC, Schisler J, Mason CE, Chatterjee A, Meller R, Beheshti A. The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection. bioRxiv. 2021 Apr 27. PMID: 33948587.
      Citations:    
    3. Ziemniak M, Zawadzka-Kazimierczuk A, Pawledzio S, Malinska M, Soltyka M, Trzybinski D, Kozminski W, Skora S, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. Int J Mol Sci. 2021 Apr 02; 22(7). PMID: 33918425.
      Citations:    Fields:    Translation:Cells
    4. Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2021 Jan; 3(1):122. PMID: 33340032.
      Citations:    
    5. Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 12; 2(12):1413-1426. PMID: 33230295.
      Citations: 8     Translation:HumansAnimalsCells
    6. Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994. PMID: 32605912.
      Citations: 9     Fields:    
    7. Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel). 2020 Apr 23; 13(4). PMID: 32340173.
      Citations: 2     
    8. Michel KA, Zielinski R, Walker CM, Le Roux L, Priebe W, Bankson JA, Schellingerhout D. Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. Radiology. 2019 10; 293(1):168-173. PMID: 31385757.
      Citations: 5     Fields:    Translation:AnimalsCells
    9. Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AG. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. Tissue Eng Part A. 2017 01; 23(1-2):80-89. PMID: 27923328.
      Citations: 8     Fields:    Translation:HumansCells
    10. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29923182.
      Citations: 11     Fields:    Translation:Humans
    11. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28417283.
      Citations:    Fields:    Translation:HumansCells
    12. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28825042.
      Citations: 5     
    13. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26861698.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    14. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15253137.
      Citations: 2     Fields:    Translation:HumansCells
    15. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25465288.
      Citations: 5     Fields:    Translation:HumansCells
    16. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24804649.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    17. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25146330.
      Citations:    Fields:    Translation:HumansCells
    18. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33981979.
      Citations: 2     
    19. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 34624208.
      Citations:    Fields:    Translation:HumansAnimalsCells
    20. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1916176.
      Citations: 2     Fields:    Translation:Humans
    21. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2194651.
      Citations: 9     Fields:    Translation:Animals
    22. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8194162.
      Citations: 2     Fields:    Translation:HumansCells
    23. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17072745.
      Citations: 2     Fields:    Translation:HumansCells
    24. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18794085.
      Citations: 62     Fields:    Translation:AnimalsCells
    25. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20921210.
      Citations: 39     Fields:    Translation:HumansAnimals
    26. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20192118.
      Citations: 14     Fields:    Translation:AnimalsCells
    27. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21692052.
      Citations: 60     Fields:    Translation:HumansCells
    28. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21855629.
      Citations: 20     Fields:    Translation:HumansCells
    29. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22249692.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    30. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23359207.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    31. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3242811.
      Citations:    Fields:    Translation:Cells
    32. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6548219.
      Citations: 3     Fields:    Translation:Animals
    33. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8270495.
      Citations:    Fields:    Translation:HumansCells
    34. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8995506.
      Citations: 2     Fields:    
    35. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9815933.
      Citations: 1     Fields:    Translation:AnimalsCells
    36. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11172688.
      Citations:    Fields:    Translation:HumansAnimalsCells
    37. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11960601.
      Citations: 10     Fields:    Translation:HumansCells
    38. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15105117.
      Citations: 16     Fields:    Translation:HumansCells
    39. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 4092212.
      Citations: 1     Fields:    Translation:Cells
    40. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9096663.
      Citations: 3     Fields:    Translation:HumansCells
    41. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8646789.
      Citations: 1     Fields:    Translation:Cells
    42. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9647783.
      Citations: 10     Fields:    Translation:HumansCells
    43. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14750133.
      Citations: 4     Fields:    Translation:HumansCells
    44. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16319532.
      Citations: 44     Translation:HumansCells
    45. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16366602.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    46. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21340606.
      Citations: 1     Fields:    Translation:HumansCells
    47. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8500223.
      Citations: 4     Fields:    Translation:Animals
    48. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8695811.
      Citations: 11     Fields:    Translation:HumansCells
    49. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9443942.
      Citations: 13     Fields:    Translation:Humans
    50. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8622633.
      Citations: 53     Fields:    Translation:AnimalsCells
    51. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11172689.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    52. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11494869.
      Citations: 13     Fields:    Translation:HumansCells
    53. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16158963.
      Citations: 2     Fields:    Translation:HumansCells
    54. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17234779.
      Citations: 75     Fields:    Translation:HumansCells
    55. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18159130.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    56. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19625015.
      Citations: 3     Fields:    Translation:Cells
    57. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 4092210.
      Citations:    Fields:    Translation:Cells
    58. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21183952.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    59. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7563208.
      Citations: 5     Fields:    Translation:Humans
    60. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8457713.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    61. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12). PMID: 27576731.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    62. Priebe W. Obituary: Derek Horton (1933-2015). Glycoconj J. 2015 Nov; 32(8):557-8. PMID: 26498188.
      Citations:    Fields:    Translation:Humans
    63. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells. 2015 Aug; 33(8):2400-15. PMID: 25966666.
      Citations: 80     Fields:    Translation:HumansCells
    64. Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget. 2015 Apr 30; 6(12):10016-29. PMID: 25881542.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    65. Mansilla S, Vizcaíno C, Rodríguez-Sánchez MA, Priebe W, Portugal J. Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells. J Cell Mol Med. 2015 Apr; 19(4):786-98. PMID: 25689150.
      Citations: 1     Fields:    Translation:HumansCells
    66. Kalinowska M, Bielawska A, Lewandowska-Siwkiewicz H, Priebe W, Lewandowski W. Apples: content of phenolic compounds vs. variety, part of apple and cultivation model, extraction of phenolic compounds, biological properties. Plant Physiol Biochem. 2014 Nov; 84:169-188. PMID: 25282014.
      Citations: 28     Translation:Animals
    67. Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL. Integrative biological analysis for neuropsychopharmacology. Neuropsychopharmacology. 2014 Jan; 39(1):5-23. PMID: 23800968.
      Citations: 7     Fields:    Translation:HumansAnimals
    68. Mielecki M, Krawiec K, Kiburu I, Grzelak K, Zagórski W, Kierdaszuk B, Kowa K, Fokt I, Szymanski S, Swierk P, Szeja W, Priebe W, Lesyng B, LaRonde-LeBlanc N. Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta. 2013 Jul; 1834(7):1292-301. PMID: 23523885.
      Citations: 8     Fields:    Translation:Cells
    69. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. Carbohydr Res. 2013 Mar 07; 368:111-9. PMID: 23376241.
      Citations: 2     Fields:    Translation:Cells
    70. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45. PMID: 22753228.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    71. Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther. 2012 Jun; 13(8):657-70. PMID: 22555804.
      Citations: 13     Translation:HumansAnimalsCells
    72. Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, Skora S, Priebe W, Bi Y, Tang DG. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One. 2011; 6(9):e24397. PMID: 21935404.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    73. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 2011 Sep 13; 20(3):384-99. PMID: 21907928.
      Citations: 60     Fields:    Translation:AnimalsCells
    74. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17. PMID: 21792892.
      Citations: 12     Fields:    Translation:AnimalsCells
    75. Mansilla S, Priebe W, Portugal J. Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters. Biochim Biophys Acta. 2011 Jul; 1809(7):327-36. PMID: 21684359.
      Citations: 1     Fields:    Translation:HumansCells
    76. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195. PMID: 21283755.
      Citations: 84     Fields:    Translation:HumansCells
    77. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov; 12(11):1113-25. PMID: 20667896.
      Citations: 275     Fields:    Translation:HumansCells
    78. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther. 2010 Jul; 9(7):2026-36. PMID: 20606045.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    79. He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res. 2010 May 07; 9(5):2098-108. PMID: 20199106.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    80. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61. PMID: 20388845.
      Citations: 22     Fields:    Translation:AnimalsCells
    81. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010 Jan; 9(1):67-78. PMID: 20053772.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    82. Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res. 2010 Jan; 9(1):430-43. PMID: 19899826.
      Citations: 40     Fields:    Translation:HumansCells
    83. Gao H, Priebe W, Glod J, Banerjee D. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells. 2009 Apr; 27(4):857-65. PMID: 19350687.
      Citations: 73     Fields:    Translation:HumansCells
    84. Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106. PMID: 20214040.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    85. Korchowiec J, Korchowiec B, Priebe W, Rogalska E. DFT study on the selectivity of complexation of metal cations with a dioxadithia crown ether ligand. J Phys Chem A. 2008 Dec 25; 112(51):13633-40. PMID: 19055400.
      Citations:    Fields:    Translation:Cells
    86. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35. PMID: 19088040.
      Citations: 94     Fields:    Translation:HumansCells
    87. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32. PMID: 19002459.
      Citations: 37     Fields:    Translation:HumansCells
    88. Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov. 2008 Nov; 3(3):179-88. PMID: 18991807.
      Citations: 11     Fields:    Translation:HumansCells
    89. van Schalkwyk DA, Priebe W, Saliba KJ. The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. J Pharmacol Exp Ther. 2008 Nov; 327(2):511-7. PMID: 18713952.
      Citations: 21     Fields:    Translation:AnimalsCells
    90. Corvis Y, Korchowiec B, Korchowiec J, Badis M, Mironiuk-Puchalska E, Fokt I, Priebe W, Rogalska E. Complexation of metal ions in Langmuir films formed with two amphiphilic dioxadithia crown ethers. J Phys Chem B. 2008 Sep 04; 112(35):10953-63. PMID: 18698707.
      Citations: 1     Fields:    
    91. Bednarek E, Sitkowski J, Kawecki R, Kozerski L, Bocian W, Pazderski L, Priebe W. Structure and dynamics of methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside complexes with PtCl(2) and PdCl(2), by (1)H, (2)H, (13)C, (15)N and (195)Pt NMR spectroscopy in DMSO, CD(3)CN and H(2)O. Dalton Trans. 2008 Aug 21; (31):4129-37. PMID: 18688431.
      Citations:    Fields:    
    92. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96. PMID: 18245540.
      Citations: 28     Fields:    Translation:HumansCells
    93. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 01; 67(23):11291-9. PMID: 18056455.
      Citations: 55     Fields:    Translation:HumansCells
    94. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6. PMID: 17942891.
      Citations: 127     Fields:    Translation:HumansAnimalsCells
    95. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Fokt I, Priebe W. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). 2007 May-Jun; 55(3):193-8. PMID: 17557149.
      Citations: 2     Fields:    Translation:HumansCells
    96. Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs. 2007 Aug; 25(4):313-26. PMID: 17483874.
      Citations: 43     Fields:    Translation:HumansCells
    97. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 2007 Apr 15; 109(8):3470-8. PMID: 17202319.
      Citations: 36     Fields:    Translation:AnimalsCells
    98. Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol. 2007 Oct; 60(5):625-33. PMID: 17195067.
      Citations: 3     Fields:    Translation:HumansCells
    99. Mansilla S, Rojas M, Bataller M, Priebe W, Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem Pharmacol. 2007 Apr 01; 73(7):934-42. PMID: 17217917.
      Citations: 3     Fields:    Translation:HumansCells
    100. Bidwell GL, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol. 2007 Mar 01; 73(5):620-31. PMID: 17161827.
      Citations: 43     Fields:    Translation:HumansCells
    101. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007 Apr 12; 26(17):2435-44. PMID: 17043651.
      Citations: 156     Fields:    Translation:HumansCells
    102. Anuszewska E, Chlopkiewicz B, Gruber B, Marczewska J, Priebe W, Skurzak H. Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Pol Pharm. 2006 Jul-Aug; 63(4):321-4. PMID: 17203872.
      Citations: 1     Fields:    Translation:HumansCells
    103. Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. Eur J Pharmacol. 2006 Jul 01; 540(1-3):34-45. PMID: 16735036.
      Citations: 5     Fields:    Translation:HumansCells
    104. Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol. 2006 Dec; 58(6):725-34. PMID: 16555088.
      Citations: 28     Fields:    Translation:HumansCells
    105. Gruber BM, Anuszewska EL, Roman I, Gozdzik A, Priebe W, Fokt I. Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Pol Pharm. 2006 Jan-Feb; 63(1):15-8. PMID: 17515324.
      Citations: 1     Fields:    Translation:HumansCells
    106. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res. 2005 May-Jun; 25(3B):1841-50. PMID: 16158916.
      Citations: 8     Fields:    Translation:HumansCells
    107. Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas. 2005 Mar; 30(2):e34-9. PMID: 15714127.
      Citations: 23     Fields:    Translation:HumansCells
    108. Chlopkiewicz B, Ejchart A, Marczewska J, Anuszewska E, Priebe W. Evaluation of mutagenic and genotoxic activities of new derivatives of anthracyclines. Acta Pol Pharm. 2005 Mar-Apr; 62(2):99-104. PMID: 16161349.
      Citations:    Fields:    Translation:HumansAnimalsCells
    109. Nair RR, Wang H, Jamaluddin MS, Fokt I, Priebe W, Boyd DD. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol Res. 2005; 15(5):265-79. PMID: 16261846.
      Citations: 1     Fields:    Translation:HumansCells
    110. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Priebe W, Fokt I. Constitutive activation of transcription factor NFkappaB as a possible marker of sensitivity of neoplastic cells to anthracyclines. Acta Pol Pharm. 2005 Jan-Feb; 62(1):17-23. PMID: 16022489.
      Citations:    Fields:    Translation:Cells
    111. Marczewska J, Anuszewska EL, Priebe W. The application of the sister chromatid exchange test for evaluation of the novel anthracycline derivatives. Part I. Acta Pol Pharm. 2004 Dec; 61 Suppl:22-4. PMID: 15909928.
      Citations:    Fields:    Translation:HumansCells
    112. Trevino AV, Woynarowska BA, Herman TS, Priebe W, Woynarowski JM. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Mol Cancer Ther. 2004 Nov; 3(11):1403-10. PMID: 15542779.
      Citations: 5     Translation:HumansCells
    113. Inge TH, Harris NL, Wu J, Azizkhan RG, Priebe W. WP744 is a novel anthracycline with enhanced activity against neuroblastoma. J Surg Res. 2004 Oct; 121(2):187-96. PMID: 15501458.
      Citations: 2     Fields:    Translation:HumansCells
    114. Fox KR, Webster R, Phelps RJ, Fokt I, Priebe W. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur J Biochem. 2004 Sep; 271(17):3556-66. PMID: 15317591.
      Citations:    Fields:    Translation:Cells
    115. Mansilla S, Priebe W, Portugal J. Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry. 2004 Jun 15; 43(23):7584-92. PMID: 15182200.
      Citations: 7     Fields:    Translation:HumansCells
    116. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol. 2004 Jan 15; 67(2):353-64. PMID: 14698047.
      Citations: 21     Fields:    Translation:HumansCells
    117. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004 Jan 01; 64(1):31-4. PMID: 14729604.
      Citations: 178     Fields:    Translation:HumansAnimalsCells
    118. Pawlowska J, Priebe W, Paine MJ, Wolf CR, Borowski E, Tarasiuk J. The ability of new sugar-modified derivatives of antitumor anthracycline, daunorubicin, to stimulate NAD(P)H oxidation in different cellular oxidoreductase systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2004; 14(10):469-74. PMID: 15559760.
      Citations: 1     Fields:    Translation:Cells
    119. Fuks L, Samochocka K, Anulewicz-Ostrowska R, Kruszewski M, Priebe W, Lewandowski W. Structure and biological activity of cationic [PtLCl(DMSO)]NO(3).DMSO complex containing a chelated diaminosugar: methyl-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxopyranoside. Eur J Med Chem. 2003 Jul-Aug; 38(7-8):775-80. PMID: 12932909.
      Citations: 1     Fields:    Translation:AnimalsCells
    120. Haj HT, Salerno M, Priebe W, Kozlowski H, Garnier-Suillerot A. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem Biol Interact. 2003 Jun 15; 145(3):349-58. PMID: 12732461.
      Citations: 6     Fields:    Translation:Cells
    121. Villamarín S, Mansilla S, Ferrer-Miralles N, Priebe W, Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur J Biochem. 2003 Feb; 270(4):764-70. PMID: 12581216.
      Citations: 5     Fields:    Translation:HumansCells
    122. Kruszewski M, Bouzyk E, Oldak T, Samochocka K, Fuks L, Lewandowski W, Fokt I, Priebe W. Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratog Carcinog Mutagen. 2003; Suppl 1:1-11. PMID: 12616592.
      Citations: 2     Fields:    Translation:AnimalsCells
    123. Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol. 2002 Dec 15; 64(12):1745-51. PMID: 12445863.
      Citations: 32     Fields:    Translation:HumansCells
    124. Inge TH, Casson LK, Priebe W, Trent JO, Georgeson KE, Miller DM, Bates PJ. Importance of Sp1 consensus motifs in the MYCN promoter. Surgery. 2002 Aug; 132(2):232-8. PMID: 12219017.
      Citations: 5     Fields:    Translation:HumansCells
    125. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):6-8. PMID: 12111105.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    126. Salerno M, Przewloka T, Fokt I, Priebe W, Garnier-Suillerot A. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochem Pharmacol. 2002 Apr 15; 63(8):1471-9. PMID: 11996888.
      Citations: 1     Fields:    Translation:HumansCells
    127. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84. PMID: 11911247.
      Citations: 2     Fields:    Translation:HumansCells
    128. Loetchutinat C, Heywang C, Priebe W, Garnier-Suillerot A. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin. Biochem Pharmacol. 2001 Sep 01; 62(5):561-7. PMID: 11585053.
      Citations: 1     Fields:    Translation:HumansCells
    129. Loetchutinat C, Priebe W, Garnier-Suillerot A. Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells. Eur J Biochem. 2001 Aug; 268(16):4459-67. PMID: 11502206.
      Citations: 6     Fields:    Translation:HumansCells
    130. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry. 2001 May 08; 40(18):5542-7. PMID: 11331019.
      Citations: 52     Fields:    Translation:HumansCells
    131. Frézard F, Pereira-Maia E, Quidu P, Priebe W, Garnier-Suillerot A. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur J Biochem. 2001 Mar; 268(6):1561-7. PMID: 11248673.
      Citations: 4     Fields:    Translation:HumansCells
    132. Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, Loetchutinat C, Fokt I, Krawczyk M, Kowalczyk T, Priebe W. Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr Med Chem. 2001 Jan; 8(1):51-64. PMID: 11172692.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    133. Hu Y, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol. 2000 Dec 15; 60(12):1897-905. PMID: 11108806.
      Citations: 9     Fields:    Translation:HumansCells
    134. Marbeuf-Gueye C, Priebe W, Garnier-Suillerot A. Multidrug resistance protein functionality: no effect of intracellular or extracellular pH changes. Biochem Pharmacol. 2000 Nov 15; 60(10):1485-9. PMID: 11020450.
      Citations:    Fields:    Translation:HumansCells
    135. Qu X, Trent JO, Fokt I, Priebe W, Chaires JB. Allosteric, chiral-selective drug binding to DNA. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):12032-7. PMID: 11027298.
      Citations: 26     Fields:    Translation:Cells
    136. Hooijberg JH, Pinedo HM, Vrasdonk C, Priebe W, Lankelma J, Broxterman HJ. The effect of glutathione on the ATPase activity of MRP1 in its natural membranes. FEBS Lett. 2000 Mar 03; 469(1):47-51. PMID: 10708754.
      Citations: 6     Fields:    Translation:HumansCells
    137. Rudnicki WR, Kurzepa M, Szczepanik T, Priebe W, Lesyng B. A simple model for predicting the free energy of binding between anthracycline antibiotics and DNA. Acta Biochim Pol. 2000; 47(1):1-9. PMID: 10961673.
      Citations: 2     Fields:    
    138. Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol. 2000; 46(5):427-32. PMID: 11127949.
      Citations: 3     Fields:    Translation:Humans
    139. Martín B, Vaquero A, Priebe W, Portugal J. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res. 1999 Sep 01; 27(17):3402-9. PMID: 10446226.
      Citations: 16     Fields:    Translation:HumansCells
    140. Marbeuf-Gueye C, Ettori D, Priebe W, Kozlowski H, Garnier-Suillerot A. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Biochim Biophys Acta. 1999 Jul 08; 1450(3):374-84. PMID: 10395948.
      Citations: 11     Fields:    Translation:HumansCells
    141. Tarasiuk J, Tkaczyk-Gobis K, Stefañska B, Dzieduszycka M, Priebe W, Martelli S, Borowski E. The role of structural factors of anthraquinone compounds and their quinone-modified analogues in NADH dehydrogenase-catalysed oxygen radical formation. Anticancer Drug Des. 1998 Dec; 13(8):923-39. PMID: 10335267.
      Citations:    Fields:    Translation:Cells
    142. Dutta R, Gao YG, Priebe W, Wang AH. Binding of the modified daunorubicin WP401 adjacent to a T-G base pair induces the reverse Watson-Crick conformation: crystal structures of the WP401-TGGCCG and WP401-CGG[br5C]CG complexes. Nucleic Acids Res. 1998 Jun 15; 26(12):3001-5. PMID: 9611247.
      Citations: 2     Fields:    Translation:Cells
    143. Leng F, Priebe W, Chaires JB. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry. 1998 Feb 17; 37(7):1743-53. PMID: 9485299.
      Citations: 14     Fields:    Translation:AnimalsCells
    144. Robinson H, Priebe W, Chaires JB, Wang AH. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. Biochemistry. 1997 Jul 22; 36(29):8663-70. PMID: 9289011.
      Citations: 9     Fields:    Translation:Cells
    145. Hu GG, Shui X, Leng F, Priebe W, Chaires JB, Williams LD. Structure of a DNA-bisdaunomycin complex. Biochemistry. 1997 May 20; 36(20):5940-6. PMID: 9166763.
      Citations: 6     Fields:    
    146. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, Priebe W. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry. 1997 Mar 04; 36(9):2679-85. PMID: 9054575.
      Citations: 14     Fields:    Translation:AnimalsCells
    147. Chaires JB, Leng F, Przewloka T, Fokt I, Ling YH, Perez-Soler R, Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem. 1997 Jan 31; 40(3):261-6. PMID: 9022792.
      Citations: 9     Fields:    Translation:HumansCells
    148. Gallois L, Fiallo M, Laigle A, Priebe W, Garnier-Suillerot A. The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids. Eur J Biochem. 1996 Nov 01; 241(3):879-87. PMID: 8944778.
      Citations: 11     Fields:    
    149. Broxterman HJ, Heijn M, Lankelma J. Re: How does the MRP/GS-X pump export doxorubicin? J Natl Cancer Inst. 1996 Apr 03; 88(7):466-8. PMID: 8618244.
      Citations:    Fields:    Translation:HumansAnimalsCells
    150. Chaires JB, Satyanarayana S, Suh D, Fokt I, Przewloka T, Priebe W. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry. 1996 Feb 20; 35(7):2047-53. PMID: 8652545.
      Citations: 28     Fields:    Translation:AnimalsCells
    151. Zou Y, Ling YH, Reddy S, Priebe W, Perez-Soler R. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int J Cancer. 1995 May 29; 61(5):666-71. PMID: 7768640.
      Citations: 4     Fields:    Translation:Animals
    152. Ling YH, Zou Y, Priebe W, Perez-Soler R. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. Int J Cancer. 1995 May 04; 61(3):402-8. PMID: 7729954.
      Citations:    Fields:    Translation:HumansCells
    153. Borrel MN, Fiallo M, Priebe W, Garnier-Suillerot A. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. FEBS Lett. 1994 Dec 19; 356(2-3):287-99. PMID: 7805856.
      Citations: 3     Fields:    Translation:HumansCells
    154. Zhao JY, Savaraj N, Song R, Priebe W, Kuo MT. Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicin. Anticancer Res. 1994 Sep-Oct; 14(5A):1735-42. PMID: 7531410.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    155. Solary E, Ling YH, Perez-Soler R, Priebe W, Pommier Y. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Int J Cancer. 1994 Jul 01; 58(1):85-94. PMID: 8014019.
      Citations:    Fields:    Translation:HumansCells
    156. Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. 1994 Mar 15; 54(6):1479-84. PMID: 8137251.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    157. Priebe W, Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther. 1993 Nov; 60(2):215-34. PMID: 8022858.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    158. Zou Y, Hayman A, Priebe W, Perez-Soler R. Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography. J Pharm Sci. 1993 Nov; 82(11):1151-4. PMID: 8289131.
      Citations:    Fields:    Translation:Animals
    159. Ling Y, Priebe W, Perezsoler R. Intrinsic cytotoxicity and reversal of multidrug-resistance by monensin in kb parent and mdr cells. Int J Oncol. 1993 Nov; 3(5):971-7. PMID: 21573461.
      Citations: 1     Fields:    
    160. Horton D, Issa M, Priebe W, Sznaidman ML. Synthesis of 3-deoxyaldulosonic acid esters by one-carbon chain extension of glycal-derived lactone precursors. Carbohydr Res. 1993 Aug 17; 246:105-18. PMID: 8370034.
      Citations:    Fields:    Translation:Cells
    161. Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res. 1993 Apr 15; 53(8):1845-52. PMID: 8467504.
      Citations: 26     Fields:    Translation:AnimalsCells
    162. Ling YH, Priebe W, Yang LY, Burke TG, Pommier Y, Perez-Soler R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res. 1993 Apr 01; 53(7):1583-9. PMID: 8453627.
      Citations: 9     Fields:    Translation:Animals
    163. Lothstein L, Hosey LM, Sweatman TW, Koseki Y, Dockter M, Priebe W. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance. Oncol Res. 1993; 5(6-7):229-34. PMID: 7907237.
      Citations: 1     Fields:    Translation:AnimalsCells
    164. Priebe W, Neamati N, Perez-soler R. 3'-Hydroxyesorubicin halogenated at C-2'. J Antibiot (Tokyo). 1992 Mar; 45(3):386-93. PMID: 1577666.
      Citations:    Fields:    Translation:Animals
    165. Perez-Soler R, Priebe W. Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. Cancer Chemother Pharmacol. 1992; 30(4):267-71. PMID: 1643693.
      Citations: 1     Fields:    Translation:AnimalsCells
    166. Horton D, Priebe W, Sznaidman M. Iodoalkoxylation of 1,5-anhydro-2-deoxy-hex-1-enitols (glycals). Carbohydr Res. 1990 Sep 19; 205:71-86. PMID: 2276153.
      Citations: 1     Fields:    Translation:Cells
    167. Priebe W, Neamati N, Perez-Soler R. 3'-Hydroxyesorubicin. Synthesis and antitumor activity. J Antibiot (Tokyo). 1990 Jul; 43(7):838-46. PMID: 2387778.
      Citations:    Fields:    Translation:AnimalsCells
    168. Horton D, Priebe W, Carter JP, Filppi J, Wolgemuth RL. 4-Demethoxy-3'-N-trifluoroacetyldoxorubicin. Synthesis and solid tumor activity. Drug Des Deliv. 1990 Jun; 6(2):123-9. PMID: 2080980.
      Citations:    Fields:    Translation:AnimalsCells
    169. Horton D, Priebe W, Sznaidman M. Preparation of 4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-3-trifluoroacetamido-L- lyxo-hex-1-enitol, a key intermediate in synthesis of daunosamine glycosides. Carbohydr Res. 1989 Apr 01; 187(1):145-8. PMID: 2752388.
      Citations:    Fields:    
    170. Horton D, Priebe W, Sznaidman M. A new approach to 2-deoxyglycosides permitting access to anthracycline glycosides specifically labeled at the 2'-position. Carbohydr Res. 1989 Apr 01; 187(1):149-53. PMID: 2752389.
      Citations:    Fields:    
    171. Priebe WM. The endoscopic appearance of Burkitt's lymphoma involving the stomach and colon. Gastrointest Endosc. 1986 Oct; 32(5):352-4. PMID: 3770388.
      Citations: 2     Fields:    Translation:Humans
    172. Horton D, Priebe W, Varela O. Selective silylation of 6-deoxyglycals. Carbohydr Res. 1985 Dec 01; 144(2):325-30. PMID: 4092211.
      Citations: 1     Fields:    
    173. Horton D, Priebe W, Varela O. Synthesis and antitumor activity of 2'-bromo- and 2'-chloro-3'-acetoxy-3'-deaminodaunorubicin analogs. Carbohydr Res. 1985 Dec 01; 144(2):305-15. PMID: 4092209.
      Citations:    Fields:    Translation:Animals
    174. Cheung TM, Horton D, Priebe W, Turner WR, Weckerle W. Sugar-ring analogs of daunorubicin: 3'-epidaunorubicin, 3'-hydroxy-3',5'-diepidaunorubicin and 3',6'-dihydroxy-3',5'-diepidaunorubicin. J Antibiot (Tokyo). 1985 May; 38(5):683-6. PMID: 4019314.
      Citations:    Fields:    Translation:Animals
    175. Horton D, Priebe W. Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2'-halo daunorubicin analogs. Carbohydr Res. 1985 Feb 28; 136:391-6. PMID: 4005892.
      Citations: 1     Fields:    
    176. Horton D, Priebe W, Varela O. 3'-Deamino-4'-epi-3'-hydroxy-daunorubicin and -doxorubicin. Synthesis and antitumor activity. J Antibiot (Tokyo). 1984 Dec; 37(12):1635-41. PMID: 6549317.
      Citations: 1     Fields:    Translation:Animals
    177. Priebe WM, Simon JB. Crohn's disease of the stomach with outlet obstruction: a case report and review of therapy. J Clin Gastroenterol. 1983 Oct; 5(5):441-5. PMID: 6415159.
      Citations: 3     Fields:    Translation:Humans
    178. Horton D, Priebe W. 14-esters of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)adriamycinone: synthesis and antitumor activity. J Antibiot (Tokyo). 1983 Sep; 36(9):1211-5. PMID: 6630080.
      Citations: 1     Fields:    Translation:Animals
    179. Priebe WM, DaCosta LR, Beck IT. Is epigastric tenderness a sign of peptic ulcer disease? Gastroenterology. 1982 Jan; 82(1):16-9. PMID: 7053328.
      Citations: 4     Fields:    Translation:Humans
    180. Horton D, Priebe W. New adriamycin analogs. Synthesis and antitumor activity of 14-substituted 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)daunomycinones. J Antibiot (Tokyo). 1981 Aug; 34(8):1019-25. PMID: 7319917.
      Citations:    Fields:    Translation:Animals
    181. Horton D, Priebe W, Turner WR. Synthesis and antitumor activity of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)adriamycinone. Carbohydr Res. 1981 Jul 16; 94(1):11-25. PMID: 7260960.
      Citations:    Fields:    Translation:Animals
    182. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget. 6:10016-10029.
    183. Nawiazanie polsko-amerykanskiej wspólpracy w dziedzinie badan translacyjnych w chorobach nowotworowych. Nowotwory. 62:491-492.
    184. Novel synthesis of anomeric peroxides and hydroperoxides. Polish Journal of Chemistry. 73:1917-1920.
    185. 2-Deoxy-1-O-silylated-β-hexopyranoses. Useful glycosyl donors and synthetic intermediates. Tetrahedron Letters. 32:2079-2082.
    186. Synthesis of antitumor-active (7S,9S)-4-demethoxy-7-O-(2,6-dideoxy-2-iodo-α-l-mannopyranosyl)adriamycinone. Carbohydrate Research. 130.
    187. Base specific and regioselective chemical cross-linking of daunorubicin to DNA. Journal of the American Chemical Society. 118:4731-4738.
    188. Interaction of doxorubicin and its derivatives with DNA. Biospectroscopy. 3:307-316.
    189. Synthetic routes to higher-carbon sugars. Reaction of lactones with 2-lithio-,3-dithiane. Carbohydrate Research. 94:27-41.
    190. Vibrational studies of Pt(II) and Pd(II) complexation by 3,4-diamino lyxo-hexopyranoside. Journal of Molecular Structure. 614:203-209.
    191. Base specific and regioselective chemical cross-linking of daunorubicin to DNA. Journal of the American Chemical Society. 118.
    192. Intrinsic cytotoxicity and reversal of multidrug-resistance by monensin in KB parent and MDR cells. International Journal of Oncology. 3:971-977.
    193. Apples. Plant Physiology and Biochemistry. 84:169e188.
    194. Platinum(II) and palladium(II) complexes with methyl 3,4-diamino-2,3,4,6- tetradeoxy-α-L-lyxo-hexopyranoside. Dalton Transactions. 2177-2183.
    195. Bioorganic and Medicinal Chemistry Letters. 5:1807-1812.
    196. Steric and conformational effects in the dehalogenation of 2-halo sugar derivatives with tributylstannane. Journal of Organic Chemistry. 58:1821-1826.
    197. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry. 35.
    198. Synthesis of 1-O-silylated 3-azido- and 3-N-trifluoroacetamido-2,3,6- trideoxy-L-arabino and L-lyxo-hexopyranoses, convenient glycosyl donors for preparation of anthracycline antibiotics and related DNA-binding agents. Polish Journal of Chemistry. 79:335-347.
    199. Magnetic Resonance in Chemistry. 25:161-165.
    200. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent anti-tumor activity in glioma cells. Cancer Biology and Therapy. 13:658-671.
    201. The comparison of the influence of ionic potential and electronegativity of selected metals and halogens on the electronic system of benzoic acid. Canadian Journal of Applied Spectroscopy. 41:144-149.
    202. The influence of selected metals and halogens on the electronic system of benzoic acid. Fresenius' Journal of Analytical Chemistry. 355:750-752.
    203. 13C NMR spectra of allosteric effectors of hemoglobin. Magnetic Resonance in Chemistry. 32:182-183.
    204. Targeting DNA with anthracyclines. Molecules. 5:299-301.
    205. A facile and selective oxidation of sulfides to sulfones. Tetrahedron Letters. 32:7353-7356.
    206. A facile transformation of benzylated methyl glycosides to thioglycosides. Polish Journal of Chemistry. 70:1270-1273.
    207. Halogenation of 1,5-anhydrohex-1-enitols (glycals). Influence of the C-6 substituent. Journal of Organic Chemistry. 51:3479-3485.
    208. Vibrational study of alkaline metal nicotinates, benzoates and salicylates. Journal of Molecular Structure. 604:189-193.
    209. Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells. Journal of Cellular and Molecular Medicine. 19:786-798.
    210. The use of liposomes as carriers of lipophilic anthracycline antibiotics. Journal of Liposome Research. 4:555-573.
    211. Current medical chemistry. Current Medicinal Chemistry. 8.
    212. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Journal of Translational Medicine.
    213. Synthesis of new 1-C-(2-furyl)-and 3-C-(2-furyl)-hexopyranosides and 3-C-(2-furyl)-daunorubicin analogs - Short communication. Monatshefte für Chemie Chemical Monthly. 122:419-423.
    214. Synthesis of alkyl 4,6-di-o-acetyl-2,3-dideoxy-α-d-threo-hex-2- enopyranosides from 3,4,6-tri-o-acetyl-1,5-anhydro-2-deoxy- d-lyxo-hex-1-enitol (3,4,6-tri-o-acetyl-d-galactal). Carbohydrate Research. 68:33-41.
    215. One step C-acylation of glycals and 2-deoxy-hexopyranoses at C-2. Tetrahedron Letters. 33:7681-7684.
    216. Configuration and conformation of methyl 2,3-anhydro-4-deoxy-pyranosides by 1H and 13C NMR spectra. Tetrahedron. 34:3325-3330.
    217. The acid-catalysed reaction of thiols with alkyl 2,3-dideoxy-glyc-2-enopyranosides or glycals. Tetrahedron. 36:287-297.
    218. Mechanism of action-governed design of anthracycline antibiotics. Current Pharmaceutical Design. 1:51-68.
    219. Editorial. Current Organic Chemistry. 12:972.
    220. New synthesis of O- and S-glycosyl derivatives of 2-chloro-3-cyano-5-nitropyridine. Heterocyclic Communications. 7:317-322.
    221. Tetrahedron Letters. 32:3313-3316.
    222. Dissection of the free energy of antheracycline antibiotic binding to DNA. Journal of the American Chemical Society. 115:5360-5364.
    223. Bromine atom interactions in biologically active acrylamide derivatives. Crystal Growth and Design. 15:2632-2642.
    224. Enantioselective high-performance liquid chromatography of chiral intermediates in the total synthesis of 4-demethoxydaunomycinone. Journal of Chromatography A. 830:191-195.
    225. Synthesis of kedarosamine, a sugar portion of the chromoprotein antibiotic kedarcidine. Polish Journal of Chemistry. 73:1143-1152.
    226. Chirality probing of chlorotetrabutyratodiruthenium(II,III) complexes with vic-amino alcohols by circular dichroism spectroscopy. Polish Journal of Chemistry. 79:387-399.
    227. New strategies towards synthesis of doxorubicin analogs. Polish Journal of Chemistry. 79:349-359.
    228. Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells. 33:2400-2415.
    PRIEBE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (698)
    Explore
    _
    Co-Authors (67)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _